Verastem Oncology Secures Debt Refinancing with Oberland Capital
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, secured a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management. In addition,...
Read moreDetails









